ArticlePeerJ2018
Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program.
Article in PeerJ, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 60 citations in OpenAlex.
- Decreasing hepatitis B seroprevalence in pregnant women in Taiwan between 2016 and 2021: a claim-based cohort study.BMC public health · 2025Article
- Article
- Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine.Annals of hematology · 2024Article
- Air pollution as a potential risk factor for hepatocellular carcinoma in Taiwanese patients after adjusting for chronic viral hepatitis.Journal of the Chinese Medical Association : JCMA · 2024Article
- The association between hepatic viral infections and cancers: a cross-sectional study in the Taiwan adult population.Clinical and experimental medicine · 2024Article
- Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Receiving Finite Periods of Antiviral Therapy.Cancers · 2023Article
- Real-World Epidemiology, Clinical and Economic Burden of Chronic Hepatitis B in Japan: A Retrospective Study Using JMDC Claims Database.Infectious diseases and therapy · 2023Article
- Epidemiology of Chronic Hepatitis B Infection in the Cohort of College Students with Vaccination in Taiwan.Vaccines · 2023Article
- Comparing the Clinical Efficacy of Coil Embolization in GDA Stump versus Common Hepatic Artery in Postoperative Hemorrhage after Pancreatoduodenectomy.Journal of personalized medicine · 2023Article
- Review
- Hepatitis B eradication: vaccine as a key player.American journal of translational research · 2023Review
- The effect of a pay-for-performance program on health-related quality of life for patients with hepatitis in Taiwan.Health and quality of life outcomes · 2022Article
- Insights into induction of the immune response by the hepatitis B vaccine.World journal of gastroenterology · 2022Review
- Different profiles of neurocognitive impairment in patients with hepatitis B and C virus infections.Scientific reports · 2022Article
- Cohort study of familial viral hepatitis and risks of paediatric cancers.International journal of epidemiology · 2022Article
- Seroprevalence and factors associated with hepatitis B virus exposure in the incarcerated population from southern Brazil.PloS one · 2022Article
- Risk of HBV infection among male and female first-time blood donors born before and after the July 1986 HBV vaccination program in Taiwan.BMC public health · 2021Article
- Mortality trends in chronic liver disease and cirrhosis from 1981 to 2015 in Taiwan.Population health metrics · 2021Article
- Developing an Evidence Base for the Delivery of Hepatitis B Virus Birth Dose Vaccination: An Evidence Map and Critical Appraisal of Systematic Reviews and Guidelines.Clinical liver disease · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, the long-term efficacy of hepatitis B virus (HBV) vaccination was assessed using seroprevalence and an age-period-cohort (APC) model of HBV seromarkers among university entrants 30 years after the introduction of the national neonatal HBV vaccination program in Taiwan.
methodsIn total, data of 17,611 university entrants who underwent university entrance health examinations between 2005 and 2016 were included. The seroprevalence of the HBV surface antigen (HBsAg) and the levels of the antibody against the HBV surface antigen (anti-HBs) in each year group and sex were calculated. The levels of the antibody against the HBV core antigen were examined only for 2012 and 2016. The APC model was used to analyze the HBV carrier rates.
resultsThe chronic HBV infection (HBsAg positivity) rate decreased from 9.7% in university students born before June 1974 to <1.0% in students born after 1992. The prevalence of anti-HBs positivity declined, particularly between the 1984-1988 cohort (78.2%-53.2%) and the 1990-1994 cohort (60.6%-44.4%). Our APC model revealed that the chronic HBV carrier rate among the student population was affected significantly by age, period, and cohort (
conclusionsHBV vaccination is one of the most effective strategies for preventing HBV infection. However, for complete eradication of HBV infection, the development of strategies that detect vaccination failure more effectively than current strategies do and early implementation of appropriate treatments are both necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.